PLAINSBORO, N.J., April 30, 2013 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the full market release of its HollywoodTM VI intervertebral body fusion device (IBD) system. The Hollywood VI IBD is used primarily in transforaminal lumbar interbody fusion (TLIF), a surgical procedure designed to help alleviate pain and nerve compression by fusing and stabilizing adjacent vertebrae in the lower back.
The Hollywood VI IBD incorporates a variable insertion feature, which enables surgeons to choose the appropriate delivery angle for the implant and gives more flexibility in managing varying patient anatomy. It includes a new, longer, 30mm implant that increases the bone graft volume by 33 percent over the current 27mm implant, and provides a larger platform to help promote spinal fusion.
"Integra has developed a TLIF cage that is simple to insert, due to the variable angle insertion mechanism, while maximizing fusion rates by aggressively increasing graft space within the cage, compared to its competitors," said Thomas N. Scioscia, M.D., OrthoVirgina, Richmond, VA.
IBDs are designed to help provide stability for spinal fusion after a diseased disc is surgically removed. They are small, hollow spinal implants that are inserted into the intervertebral space to restore physiological disc height and allow fusion between vertebral bodies. The graft window in the device is packed with bone and provides an environment in which natural bone growth can occur, which then enables fusion of the vertebral segments.
"We are always looking for ways to better serve our surgeons," said Kirt Stephenson, Integra's President, U.S. Spine. "Our new Hollywood VI IBD does just that, by providing our customers with additional solutions that help meet their patients' needs."
Integra's Hollywood VI IBD will be available at Integra's booth (629) at the 2013 AANS Annual Meeting in New Orleans, Louisiana, April 27-May 1, 2013. Integra will also offer live demonstrations and opportunities for hands-on experience of its products.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2012 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results
CONTACT: Integra LifeSciences Holdings Corporation Gianna Sabella Director, Corporate Communications 609-936-2389 Gianna.email@example.com
Source:Integra LifeSciences Holdings Corp.